Clinical Trials Logo

Filter by:
NCT ID: NCT06394310 Not yet recruiting - Multiple Sclerosis Clinical Trials

Dry Needling in Multiple Sclerosis

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The investigators are doing this study to see if a treatment called dry needling improves muscle spasticity (muscle tightness) in people who have Multiple Sclerosis. Dry needling involves using tiny needles, like those in acupuncture, to target some muscles, like calf muscles. It differs from traditional acupuncture as it focuses on treating or managing muscle spots, aiming to reduce muscle stiffness and pain. Dry needling may offer a minimally-invasive and medication-free approach to improve muscle spasticity. The investigators hope to see if dry needling also helps enhance balance and walking abilities. This might provide potential improvements inoverall mobility and balance.

NCT ID: NCT06394193 Not yet recruiting - Clinical trials for Mental Health Wellness

Va Meh Du Intervention

Start date: June 2024
Phase: N/A
Study type: Interventional

This study is a conceptually integrated community-based participatory research study that includes the design and evaluation of an intervention to promote mental wellness and physical activity for Karenni children and young adults.

NCT ID: NCT06394167 Recruiting - Pain Clinical Trials

A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults

Start date: May 9, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of intravenously administered VX-993 at different doses in healthy participants.

NCT ID: NCT06394115 Completed - Ileostomy - Stoma Clinical Trials

Assessment of Novel Technology to Facilitate Drainage in Ostomy Pouches: OUTFLOW Study

OUTFLOW
Start date: August 1, 2022
Phase:
Study type: Observational

The overall aim of this study is to determine the performance and safety of a novel coated material inside Convatec Ostomy Pouches, and to explore the clinical and quality of life benefits that may occur with the use of the test product. A minimum of 30 subjects, and a maximum of 40 subjects will be recruited to obtain 30 complete datasets comprised of a minimum of 15 colostomy and minimum of 10 ileostomies.

NCT ID: NCT06393738 Recruiting - Clinical trials for Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Start date: April 30, 2024
Phase: Phase 1
Study type: Interventional

This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.

NCT ID: NCT06393660 Available - Clinical trials for Transplant-Related Disorder

Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta for Allogenic Transplant (Expanded Access Use)

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this IDE protocol is to provide access to TCR Alpha/Beta+/CD19+ depleted allogeneic hematopoietic stem cell (HSC) in patients who require hematopoietic stem cell transplantation.

NCT ID: NCT06393634 Enrolling by invitation - Healthy Clinical Trials

Comparing Direct and Indirect Detection Methods of Multiple Routes of Testosterone Administration

T esters
Start date: May 8, 2024
Phase: Early Phase 1
Study type: Interventional

Testosterone abuse is extremely prevalent in athletes globally and especially in the United States professional sporting leagues

NCT ID: NCT06393517 Active, not recruiting - Clinical trials for Healthy Participants

A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults

Start date: April 30, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare three finished products of PF-06954522 in terms of the uptake into the blood stream. This study is seeking participants who are: - Healthy male or female participants aged 18 years or older. All participants in this study will receive PF-06954522 once by mouth. The participants may receive different tablets by mouth for PF-06954522. The study will compare experiences of people receiving three different products of PF-06954522. This will help understand how much PF-06954522 is taken up into the blood for each product given. Participants will take part into the study for about 77 days. During this time participants will have to stay onsite for 21 days. There will be one follow up (by telephone) study visit.

NCT ID: NCT06393504 Active, not recruiting - Insomnia Disorder Clinical Trials

Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)

Start date: November 30, 2023
Phase:
Study type: Observational

Healthcare claims database study to provide safety information on maternal, fetal and infant outcomes among women exposed to QUVIVIQ (daridorexant) during pregnancy

NCT ID: NCT06393465 Recruiting - Clinical trials for Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

Start date: May 19, 2024
Phase:
Study type: Observational

This study will examine the clinical effectiveness of Tafamidis in patients with Mixed Phenotype Transthyretin Amyloidosis using data that already exist in patients' medical records